SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel's stock is surging amid reports of potential investments and partnerships with major players like Apple and TSMC, building on momentum from a recent deal with Nvidia. The community is buzzing about the possibilities of these collaborations, viewing them as a sign of a significant turnaround for the chipmaker. With government backing and strategic moves underway, investors are closely watching Intel's next steps in the evolving semiconductor landscape.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies, viewing the current dip as a buying opportunity before the next leg up. Active community members emphasize the project's ongoing developments, listings on multiple exchanges, and upcoming utilities, highlighting the development team's transparency and commitment. A buy contest is currently underway to push the price to the next milestone.

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

$PUPU.X is trending as the community compares it to $PEPE.X, suggesting it could be the next big meme coin. Community members highlight its availability on Phantom Wallet and the Solana network, contributing to the increased buzz.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions about tariffs on pharmaceuticals and other goods, with community members debating the potential economic impacts. Some are referencing Trump's past statements on tariffs and trade, while others are discussing potential beneficiaries and losers from these policies. Broader conversations include political commentary and comparisons to other economic policies.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining ($CIFR) is trending due to a recently announced upsized private offering of convertible senior notes and a hosting agreement with Fluidstack backed by Google, leading to discussions about the company's AI data center strategy. While some express concerns over potential dilution, others view the deal as a strong signal of institutional confidence and a catalyst for growth, particularly given Google's equity stake and the potential for expansion in the HPC sector.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive ($DRV.X) is trending amid news of a potential collaboration with Synthetix to develop derivatives on the Ethereum network. The crypto community is actively discussing the possible implications of this partnership and anticipating future developments. Mentions of other cryptos, such as Bitcoin and Ethereum, suggest a broader interest in the derivatives space.

CarMax, Inc. is a holding company, which engages in the retail of used vehicles and wholesale of vehicle auction operators. It operates through the CarMax Sales Operations and CarMax Auto Finance (CAF) segments. The CarMax Sales Operations segment consists of all aspects of its auto merchandising and service operations. The CAF segment pertains to its finance operation, which offers vehicle financing services to customers buying retail vehicles. The company was founded by Richard L. Sharp and William Austin Ligon in 1993 and is headquartered in Richmond, VA.

Carmax Inc

CarMax ($KMX) is trending due to disappointing Q2 results, including a slump in car sales and rising loan loss provisions, leading to a breach of its 52-week low. The community is discussing whether the stock is now a bargain or if it signals broader issues in the auto industry, especially compared to competitors like Carvana. Some investors see the dip as an overreaction and buying opportunity, while others worry about debt and economic headwinds.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses its potential, particularly within the Real World Asset (RWA) space, and anticipates revenue generation from its products. Speculation around potential allocations from other projects are circulating, alongside general bullish sentiment and price target discussions. Some traders are watching for a breakout.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares

SOXS is trending as the semiconductor sector defies broader market trends, fueled by AI optimism and significant investments despite concerns of overvaluation. The community is actively discussing Intel's recent surge and potential impact, along with the sustainability of the sector's growth given high capital expenditure and competition. Some traders are considering SOXS as a hedge, while others remain skeptical amid the ongoing rally in semiconductor stocks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

Iris Energy Ltd

IREN is trending due to analyst upgrades and optimism surrounding its shift towards AI cloud services, with community members actively discussing price targets and potential deals. Some are wary of its rapid growth, suggesting it may be overvalued, while others see significant long-term potential as the company expands its GPU capacity. Bullish sentiment remains strong as IREN navigates its transition into the AI infrastructure space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates

Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -13.89% and -59.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech

Prime Medicine stock soars amid gene editing sector momentum

Investing.com --  Prime Medicine  (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for  Verve Therapeutics  (NASDAQ:VERV) last month. 

Retail chatter for Prime Medicine spiked Monday following Citi's downgrade to 'Neutral' from 'Buy,' with the price target slashed to $1.50 from $10.&nbsp;According to Citi's research note, the shares were trading near cash, reflecting investor uncertainty over the company's path to value inflection.Citi said that Prime Medicine's cash reserves will sustain operations only until mid-2026 despite recent efforts to cut costs and restructure operations.However, management expects initial clinical data will become available for Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD) in 2027.Prime Medicine’s shares closed at $1.29 on Friday, up 4.88% or $0.06 for the day.The company said it would restructure by making its Chronic Granulomatous Disease (CGD) programs a lower priority while cutting its workforce by about 25% to concentrate on the liver disease franchise and externally funded programs.The firm maintains progress in its live studies that target two significant genetic liver conditions: Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD).It plans to file an investigational new drug (IND) application in the first half of 2026 and mid-2026, respectively. Initial clinical data for these programs are expected in 2027.Prime Medicine also maintains its cystic fibrosis program, which is supported by the Cystic Fibrosis Foundation, and collaborates with Bristol Myers Squibb to develop Prime Edited CAR-T products in hematology, immunology, and oncology.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.One user noted insider buying and a technical double bottom pattern, suggesting the stock could either become a complete write-off or achieve “legendary” success.<stembedurl>https://stocktwits.com/sogenerous/message/615704325</stembedurl>Meanwhile, another user highlighted the company's gene-editing technology and its long-term potential despite the lengthy clinical timelines.<stembedurl>https://stocktwits.com/Shesellsseashells/message/615286716</stembedurl>The stock has declined 57% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Citi Downgrade Sparks Retail Chatter On Prime Medicine Amid Cash Runway Uncertainty

The biotech firm announced a restructuring to focus on its liver disease programs while cutting costs and workforce amid ongoing development challenges.

Equity

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Shares of biotechnology company Prime Medicine, Inc. (PRME) fell 18% on Monday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-announces-strategic-restructuring-focus">announced</a> a strategic restructuring, including layoffs and the resignation of its CEO in a bid to reduce cash burn.Prime Medicine announced that Keith Gottesdiener will step down as CEO and a member of the company’s board of directors, effective immediately.Allan Reine, Prime Medicine’s Chief Financial Officer (CFO), will now succeed Gottesdiener.The company also announced the deprioritization of its programs aimed at the genetic disorder Chronic Granulomatous Disease (CGD), instead focusing its efforts on the development of programs for genetic liver diseases, Wilson’s Disease, and Alpha-1 Antitrypsin Deficiency (AATD).The company expects to file an investigational new drug (IND) and/or clinical trial application (CTA) for its Wilson’s Disease program in the first half of 2026 and its AATD program in mid-2026. Initial clinical data from both programs is expected the following year.For its CGD program, PM359, the company said it is exploring options for continued clinical development outside the firm.However, the company expressed confidence in the program and believes it has the potential to transform the treatment of the disorder.Prime Medicine also said it is reducing its organizational headcount by approximately 25%.The company believes the multiple initiatives will reduce anticipated cash needs by almost half through 2027.Prime Medicine expects that its cash, cash equivalents, and investments as of March 31, 2025, will be sufficient to fund its operations and capital expenditure requirements into the first half of 2026.On Stocktwits, retail sentiment around PRME rose within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_19_at_12_06_01_PM_png_ee21a5e357.webp" alt="PRME's Sentiment Meter and Message Volume as of 12:05 p.m. ET on May 19, 2025 | Source: Stocktwits" width="628" height="65"><figcaption>PRME's Sentiment Meter and Message Volume as of 12:05 p.m. ET on May 19, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/PRME">PRME stock</a> is down by about 57% this year and 83% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/protagenic-therapeutics-merges-with-phytanix-bio/ch0cuACRb8E">Protagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish

The company said Keith Gottesdiener will step down as the chief executive, while CFO Allan Reine will succeed him.

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 30, 2025 NEW YORK...

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Prime Medicine Inc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

Current Price	$5.22
Prev Close	$5.56
Open	$5.16
Dividend Yield	0.00%
50-Day Moving Average	$4.01
Beta	1.88
Avg. Volume	3.58M
PE Ratio	-3.27

52-Week High	$5.63
52-Week Low	$1.11
Market Capitalization	$930.18M
EPS (Annual)	-$1.65
Price to Book	11.54
Revenue Per Employee	$13,939.25
Enterprise Value/EBITDA	N/A

PRME
Prime Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRME News

PRME Prime Medicine Inc